Volume : 12, Issue : 12, December- 2025
Title:
ROLE OF CLINICAL PHARMACIST IN IDENTIFYING, REPORTING AND MANGEMENT OF POTENTIAL DRUG-DRUG INTERACTION AMONG PATIENTS ADMITTED IN INTENSIVE CARE UNIT
Authors :
Asifmiya, Nameera Jahan, Shagufta Afreen
Abstract :
Aim: The study aimed to assess the role of clinical pharmacists in identifying, reporting, and managing potential drug-drug interactions (DDIs) among ICU patients. With the increasing complexity of therapeutic regimens in critically ill patients, the risk of DDIs is increases, and the involvement of clinical pharmacists is crucial .Methods and Materials: A Prospective Interventional study is carried out for a period of 6 months in intensive care units of GIMS, Kalaburgi. The study is conducted by enrolling patients admitted to intensive care unit, by considering the study criteria. From the case sheets of the enrolled patient’s demographic, data, reason for admission, co-morbidities, medical and medication history, medication chart is noted in a suitably designed data collection form. The DDIs is identified and analyzed by using Micromedex data base. The identified DDIs is brought to the notice of the physician/prescriber/PGs and possible measures is taken to avoid the interactions. The action taken by the physician/prescriber for the suggestions given by the clinical pharmacist to avoid the DDIs is also been noted. Results. Among a total of 177 patients included in study from the Intensive Care Unit (ICU) at GIMS hospital. The majority of the patients were male (55.9%), with a mean age of 52.25 years, and the most prevalent age group being 41-60 years. Hypertension (31.6%) and diabetes mellitus (18.1%) were the most common comorbidities. The average number of drugs prescribed per patient was 10.94, with 48% of patients receiving 5-10 drugs. The risk of DDIs increased with the number of medications prescribed. All 177 patients identified at least one DDI, with an average of 2.90 interactions per patient. The total number of identified DDIs was 514, with major interactions accounting for 47.86% of the cases. A significant proportion of DDIs were categorized as major (47.86%), followed by moderate (33.46%) and minor (18.6%) interactions. Common Drugs Involved in DDIs: Ondansetron , phenytoin, and furosemide were the most frequently interacting drugs, highlighting the importance of vigilant monitoring of these medications in ICU settings Study reveals that; there was statistically significant association of duration of hospital stays and DDI’s . More number of days of hospital stays patients was observed more numbers of DDI’s conclusion: The study concludes that the presence of a clinical pharmacist in the ICU can play a pivotal role in the early identification and management of potential DDIs, thus improving patient outcomes. The clinical pharmacist’s interventions, including adjustments in drug regimens, dose alterations, and frequent monitoring, were essential in minimizing the adverse effects caused by DDIs. This collaborative approach between clinical pharmacists and physicians led to a more optimized and safer medication therapy
Cite This Article:
Please cite this article in press Riyaz Miya et al., Role Of Clinical Pharmacist In Identifying, Reporting And Mangement Of Potential Drug-Drug Interaction Among Patients Admitted In Intensive Care Unit, Indo Am. J. P. Sci, 2025; 12(12).
Number of Downloads : 10
References:
1. Arvind NK, Umesh M, Shobha C. Assessment Of Drug-Drug Interactions in Hospitalised Patients in India. Asian J Pharm Clin Res 2011;4(1):62-5,.
2. Stockley HI, editor. Stockley’s Drug Interactions. 5th ed. London, Chicago: The Pharmaceutical Press; 2001.
3. Shalini S. Lynch. Drug interactions. MSD MANUAL professional version. July 22
4. Jimmy OD, Shobha Rani R, Indira R. Ramjan S. Study of Drug-Drug Interactions in the Medication Charts in Medicine Wards at a Tertiary Care Hospital Bangalore. Ind, J Pharm Pract, 2012; 5(4): 61-5.
5. Ehsan N, Hasan V, Zhila T, Saeid E. Drug-Drug Interactions in Inpatient and Outpatient Settings in Iran: A Systematic Review of the Literature, DARU J PharmlSci, 2014,22(52); 1-13.
6. Ramam S, Suresh SVK, Devanna N, Ravindra KR. Prevalence and Severity of Possible Drug-Drug Interactions in the Inpatient Department of Internal Medicine. IJPCR 2016;8(8):1212-4.
7. S. V. Doubova, H. Reyes-Morales, L. P. Torres-Arreola, and M. Suárez-Ortega. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Services Research, vol. 7, no. 1, 2007.
8. Aline TR , Rebeca S , Silvia G , Antonio LEF , Patricia M, Priscila GM. Clinical relevancy and risks of potential drug–drug interactions in intensive therapy. Saudi Pharmaceutical Journal (2015) 23, 366–370.
9. Hammes JA, pfuetzenreiter, silveira, koenig, westphal, G.A.Pottential drug interations prevalence in intensive care unit. Rev. Bras. Ter. Intensiva, v.20, n.4, p.349- 354, 2008.
10. Hamidy YM, Fauzia D. Significant drug interactions among intensive care unit patients. Asian J Pharm Clin Res. 2016;35-6.
11. Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med. 2002;9(11):1162-7.
12. Sainul A, Kalaiselvan V. Pradeep M. Assessment Of Prevalence of Potential Drug-Drug Interactions in Medical Intensive Care Unit of a Tertiary Care Hospital in India. Asian J Pharm Clin Res 2015;8(1):125-30.
13. Nashwa M, Sepehr S, Lisa K, Ellett and Gillian EC.What is polypharmacy? A systematic review of definitions. 2017; 17:230.
14. Parthasarthi G, Nyfort K, Nahata M, A text book of Clinical Pharmacy Practice 2009:105-6
15. Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmaceut Sci. 2009;12(3):266-72.
16. Karen B, Editor. Stockley’s Drug Interaction 8thedn published by Pharmaceutical press London chicago 2008: 2-10.
17. Rekha MM, Mubeena T;A study on role of Clinical Pharmacist in identification and reporting of drug interactions in Physciatric Ward in a Teritary Care Teaching Hospital; PharmaTutor; 2017; 5(5);70-75.
18. Audrey JL, Maureen SB, Katherine KK, Joy LM, and Nancy EK. Clinical and economic outcomes of pharmacist recommendations in a veterans affairs medical center, Am J Health-Syst Pharm 2002 Nov 1;59:2070
19. Debashish C, Ashish KD. Intensive care unit models: do you want them to be open or closed? A critical review. Neurol india 2017; 65:39-45.
20. Valizade H, Mohammad Al, Sharifi H, Hasanzadeh A. Drug-Drug Interactions Prevalence in Intensive Care Unit Patients of a University Hospital in Iran. Bull. Env. Pharmacol. Life Sci. 2014;3(7):87-9120
21. Zhu W, Barreto EF, Li J, Lee HK, Kashani K. Drug-drug interaction and acute kidney injury development: A correlation-based network analysis. PLoS One. 2023 Jan 6;18(1):1-17.
22. Sultana A, Singh M, Kumar A. To identify drug-drug interaction in cardiac patients in tertiary care hospitals. J Res Appl Sci Biotechnol. 2022 Aug;1(3):146-52.
23. Jiang H, Lin Y, Ren W, Fang Z, Liu Y, Tan X, Lv X, Zhang N. Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020. Front Pharmacol. 2022 Aug 22;13:1-14.
24. RoopaShree PM, Chhetri DR, Lal V. Study of drug-drug interactions in inpatients admitted to the Department of General Medicine at a tertiary care teaching hospital, Ballari, Karnataka. Indo Am J Pharm Res. 2018;8(4):998-1008.
25. Patel VK ,Acharya LD,Rajakannan T, potential drug interactions in patients admitted to cardiology ward of south indian teaching hospital . Australas med j.2011:4(1):9-14.
26. Ahmad A, Khan MU, Haque F, Nan R, Dazarf R, Revanker M, Pravina A, Kuriakose S. Evaluation of potential drug-drug interactions in general medicine ward of teaching hospital in Southern India. J Clin Diagn Res. 2015 Feb;9(2):FC10-3.
27. Acharya S, Ragam AS, Holla R, Bhat AR. Prevalence of potential drug-drug interactions in the intensive care unit of a tertiary care hospital: a cross-sectional study. J Young Pharm. 2019;11(2):197-201.
28. Krishnarajan D, Ranjini BS, Arya MS, Sunny S. Prescription analysis, drug interaction checking and impact of patient counseling by a clinical pharmacist in type II diabetes mellitus patients in a tertiary care hospital: a prospective study. Int J Pharm Pharm Sci. 2020;12(7):59-65.
29. George KG, Sundaran S, Ali CPA, Mubeena KM, Thansiya PH, Babu G, Gopalakrishnan A. Study of drug-drug interaction in the inpatients of a tertiary care hospital at Calicut. Asian J Pharm Clin Res. 2018;11(9):162-4
30. Firoz S, Muppineni D, Badithala KV, Kola R, Samanthula S. Evaluation of polypharmacy induced drug interactions of general medicine in a tertiary care hospital. Saudi J Med Pharm Sci. 2021;7(8):411-7.
31. Pourheidar E, Moslemzadeh D, Mokhtari M, Kouchek M, Miri MM, Haghighi M, Hassanpour R, Sistanizad M. The effect of the number of potential drug-drug interactions and prescribed medications on length of stay and mortality rate of patients in the intensive care unit. Int Pharm Acta. 2021;4(1):e7